Treating opportunistic infections among HIV-infected adults and adolescents: Recommendations from CDC, the national institutes of health, and the HIV medicine association/infectious diseases society of America

被引:39
作者
Benson, CA
Kaplan, JE
Masur, H
Pau, A
Holmes, KK
机构
[1] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[2] Ctr Dis Control & Prevent, Atlanta, GA USA
[3] NIH, Bethesda, MD 20892 USA
[4] Univ Washington, Seattle, WA 98195 USA
关键词
D O I
10.1086/427906
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The CDC, National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America have developed guidelines for treatment of opportunistic infections (OIs) among adults and adolescents infected with human immunodeficiency virus (HIV). These guidelines are intended for clinicians and other health-care providers who care for HIV-infected adults and adolescents, including pregnant women; they complement companion guidelines for treatment of OIs among HIV-infected children and previously published guidelines for prevention of OIs in these populations. They include evidence-based guidelines for treatment of 28 OIs caused by protozoa, bacteria, fungi, and viruses, including certain OIs endemic in other parts of the world but that might be observed in patients in the United States. Each OI section includes information on epidemiology, clinical manifestations, diagnosis, treatment recommendations, monitoring and adverse events, management of treatment failure, prevention of recurrence, and special considerations in pregnancy. Tables address drugs and doses, drug toxicities, drug interactions, adjustment of drug doses in persons with reduced renal function, and data about use of drugs in pregnant women.
引用
收藏
页码:S131 / S235
页数:105
相关论文
共 704 条
[1]  
*ABB LAB, 1995, CLAR BIAXIN
[2]   Eradication of AIDS-related disseminated Mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy [J].
Aberg, JA ;
Yajko, DN ;
Jacobson, MA .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (05) :1446-1449
[3]   Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era [J].
Abgrall, S ;
Rabaud, C ;
Costagliola, D .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (10) :1747-1755
[4]  
Adelstein SJ, 1999, TERATOLOGY, V59, P236, DOI 10.1002/(SICI)1096-9926(199904)59:4<236::AID-TERA9>3.3.CO
[5]  
2-Y
[6]  
ALBINO JA, 1994, OBSTET GYNECOL, V83, P823
[7]  
Aleck KA, 1997, AM J MED GENET, V72, P253, DOI 10.1002/(SICI)1096-8628(19971031)72:3&lt
[8]  
253::AID-AJMG1&gt
[9]  
3.0.CO
[10]  
2-S